Detalhe da pesquisa
1.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Lancet Oncol
; 19(11): 1449-1458, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30348538
2.
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
N Engl J Med
; 372(10): 944-53, 2015 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25738670
3.
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Br J Haematol
; 178(1): 61-71, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28382618
4.
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study.
Haematologica
; 102(5): 895-902, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28183846
5.
Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience.
Oncology
; 93(5): 295-301, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28803241
6.
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Am J Hematol
; 92(10): E575-E583, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28699256
7.
Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.
Br J Haematol
; 170(4): 496-503, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25921098
8.
Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience.
Oncology
; 89(4): 196-204, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26228581
9.
Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma.
J Proteome Res
; 13(2): 844-54, 2014 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24256566
10.
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Br J Haematol
; 160(5): 649-59, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23293914
11.
Soluble M6P/IGF2R released by TACE controls angiogenesis via blocking plasminogen activation.
Circ Res
; 108(6): 676-85, 2011 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21273553
12.
European perspective on multiple myeloma treatment strategies: update following recent congresses.
Oncologist
; 17(5): 592-606, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22573721
13.
Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma.
Eur J Clin Invest
; 42(9): 953-60, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22591013
14.
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Haematologica
; 97(9): 1431-8, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22511498
15.
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Oncologist
; 16(4): 388-403, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21441574
16.
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.
Blood
; 113(15): 3435-42, 2009 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-18955563
17.
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Haematologica
; 96(7): 1008-14, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21486866
18.
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Oncologist
; 15(1): 6-25, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20086168
19.
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.
Haematologica
; 95(9): 1548-54, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20418244
20.
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Ann Hematol
; 89(3): 273-82, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19693500